ENVB vs. EQ, BCDA, IBIO, SNPX, NERV, BIVI, ALVR, BTAI, AIMD, and ABP
Should you be buying Enveric Biosciences stock or one of its competitors? The main competitors of Enveric Biosciences include Equillium (EQ), BioCardia (BCDA), iBio (IBIO), Synaptogenix (SNPX), Minerva Neurosciences (NERV), BioVie (BIVI), AlloVir (ALVR), BioXcel Therapeutics (BTAI), Ainos (AIMD), and Abpro (ABP). These companies are all part of the "pharmaceutical products" industry.
Enveric Biosciences vs. Its Competitors
Enveric Biosciences (NASDAQ:ENVB) and Equillium (NASDAQ:EQ) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and dividends.
13.8% of Enveric Biosciences shares are held by institutional investors. Comparatively, 27.0% of Equillium shares are held by institutional investors. 1.1% of Enveric Biosciences shares are held by company insiders. Comparatively, 31.6% of Equillium shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Equillium has higher revenue and earnings than Enveric Biosciences. Equillium is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks.
Enveric Biosciences presently has a consensus price target of $10.00, suggesting a potential upside of 663.36%. Equillium has a consensus price target of $3.00, suggesting a potential upside of 644.97%. Given Enveric Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Enveric Biosciences is more favorable than Equillium.
Enveric Biosciences has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500. Comparatively, Equillium has a beta of 1.86, indicating that its share price is 86% more volatile than the S&P 500.
In the previous week, Enveric Biosciences had 2 more articles in the media than Equillium. MarketBeat recorded 3 mentions for Enveric Biosciences and 1 mentions for Equillium. Equillium's average media sentiment score of 1.89 beat Enveric Biosciences' score of 0.84 indicating that Equillium is being referred to more favorably in the news media.
Enveric Biosciences has a net margin of 0.00% compared to Equillium's net margin of -19.62%. Equillium's return on equity of -74.34% beat Enveric Biosciences' return on equity.
Summary
Equillium beats Enveric Biosciences on 9 of the 14 factors compared between the two stocks.
Get Enveric Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENVB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ENVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Enveric Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:ENVB) was last updated on 7/25/2025 by MarketBeat.com Staff
Free ENVB Stock Alerts